Guillaume Davidson
Overview
Explore the profile of Guillaume Davidson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cigrang M, Obid J, Nogaret M, Seno L, Ye T, Davidson G, et al.
Nat Commun
. 2025 Jan;
16(1):512.
PMID: 39779693
The plasticity of cancer cells facilitates their ability to adopt heterogeneous differentiation states, posing a significant challenge to therapeutic interventions. Specific gene expression programs, driven in part by super-enhancers (SEs),...
2.
Super-enhancer-driven expression of BAHCC1 promotes melanoma cell proliferation and genome stability
Berico P, Nogaret M, Cigrang M, Lallement A, Vand-Rajabpour F, Flores-Yanke A, et al.
Cell Rep
. 2023 Nov;
42(11):113363.
PMID: 37924516
Super-enhancers (SEs) are stretches of enhancers ensuring a high level of expression of key genes associated with cell function. The identification of cancer-specific SE-driven genes is a powerful means for...
3.
Davidson G, Helleux A, Vano Y, Lindner V, Fattori A, Cerciat M, et al.
Cancer Res
. 2023 Jun;
83(17):2952-2969.
PMID: 37335139
Significance: Single-cell and spatial transcriptomics reveal the proximity of mesenchymal tumor cells to myofibroblastic cancer-associated fibroblasts and their association with disease outcome and immune checkpoint inhibitor response in clear cell...
4.
Vokshi B, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller A, et al.
Nat Commun
. 2023 May;
14(1):3034.
PMID: 37236926
Renal medullary carcinoma (RMC) is an aggressive tumour driven by bi-allelic loss of SMARCB1 and tightly associated with sickle cell trait. However, the cell-of-origin and oncogenic mechanism remain poorly understood....
5.
Saisa-Borreill S, Davidson G, Kleiber T, Thevenot A, Martin E, Mondot S, et al.
Cell Death Differ
. 2023 Jan;
30(3):839-853.
PMID: 36639541
Taf4 (TATA-box binding protein-associated factor 4) is a subunit of the general transcription factor TFIID, a component of the RNA polymerase II pre-initiation complex that interacts with tissue-specific transcription factors...
6.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, et al.
Clin Cancer Res
. 2022 Nov;
29(7):1279-1291.
PMID: 36374555
Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with clear-cell renal cell carcinomas (ccRCC). Although analyses of transcriptome, genetic alterations, and the tumor microenvironment (TME) have shed...
7.
Gambi G, Mengus G, Davidson G, Demesmaeker E, Cuomo A, Bonaldi T, et al.
Cancer Res
. 2022 Oct;
82(24):4555-4570.
PMID: 36214632
Significance: The lncRNA LENOX is a novel regulator of melanoma metabolism, which can be targeted in conjunction with MAPK inhibitors to eradicate melanoma cells.
8.
Yao W, German B, Chraa D, Braud A, Hugel C, Meyer P, et al.
JCI Insight
. 2022 Sep;
7(21).
PMID: 36107619
Malignant melanoma is a major public health issue displaying frequent resistance to targeted therapy and immunotherapy. A major challenge lies in better understanding how melanoma cells evade immune elimination and...
9.
Mancuso P, Tricarico R, Bhattacharjee V, Cosentino L, Kadariya Y, Jelinek J, et al.
Oncogene
. 2022 May;
41(23):3300-3301.
PMID: 35505094
No abstract available.
10.
Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougouin A, Moreira M, et al.
Oncologist
. 2022 Mar;
27(6):501-511.
PMID: 35278076
Background: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) are contradictory. The TME of SMARCA4-UT...